In its final Phase 3 analysis, Trutakna (atacicept) essentially stabilized kidney function and cut disease-progression events by 76% in IgA nephropathy — strong data as Vera pushes for full FDA approval.
Pooling 139 trials, researchers found the most effective drug-free treatments for knee osteoarthritis were surprisingly simple: knee braces, water-based therapy and regular exercise — while a common clinic staple ranked near the bottom.
GSK is paying up to $750 million for global rights to Chimagen’s trispecific T-cell engager for multiple myeloma — the latest sign of the company rebuilding the oncology franchise it sold off a decade ago.
Curium’s Bexlutry, a generic of Novartis’s Lutathera, is the first “radioligand equivalent” approved in the U.S. — a milestone that could open a fast-growing but supply-constrained corner of cancer care to competition.
A detailed look inside the aging hippocampus reveals that brain aging isn’t a slow, steady slide — it’s a coordinated overhaul of the brain’s immune and blood-vessel systems that peaks in a specific midlife-to-later-life window.
Breast cancer patients with vitamin D deficiency needed more pain medicine and reported more moderate pain after mastectomy — a suggestive link, though the study can’t prove cause and effect.
Up to 1 in 5 people with high blood pressure may have a hormone disorder that standard daytime blood tests overlook — because the telltale hormone surges mostly at night.
Definium’s DT120 eased generalized anxiety in a second large Phase 3 study — positioning the company to seek what would be the first-ever approval of a psychedelic medicine for anxiety.
A pioneer of donor-derived cell therapy is walking away from cancer CAR-T — battered by competition — and pivoting to in vivo gene editing for heart disease. Investors sent the stock down 43%.
A red-light photodynamic treatment with Biofrontera’s Ameluz gel is now approved for superficial basal cell carcinoma — the first photodynamic therapy okayed for any skin cancer.
Crohn’s patients ate the same plant foods as healthy controls and had more oxalate in their stool. The difference was in the transporters, not the diet.
Wall-mounted sensors processing on-device rather than in the cloud. The architecture choice is what makes the product legally and practically deployable.